
ARQT
Healthcare · Biotechnology · $3.57B market cap
$28.26+0.73 (+2.7%)Nov 13, 4:21 PM EST
Next report
After the close
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · -13.7% over 90 days · 30-day revisions 0 up, 1 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Feb 24, 2027 · upcoming | After the close | 0.21 | — | — |
| Nov 4, 2026 | After the close | 0.17 | 0.06 | -64.7% |
| Aug 5, 2026 | After the close | 0.09 | 0.11 | +22.2% |
| May 6, 2026 | After the close | -0.06 | -0.09 | -50.0% |
| Feb 26, 2026 | Time not confirmed | 0.09 | 0.13 | +46.7% |
| Oct 28, 2025 | Before the open | -0.09 | 0.06 | +166.7% |
| Aug 6, 2025 | After the close | -0.16 | -0.13 | +18.8% |
| May 6, 2025 | After the close | -0.21 | -0.20 | +4.8% |
| Feb 25, 2025 | Before the open | -0.26 | -0.09 | +65.9% |
| Nov 6, 2024 | After the close | -0.42 | -0.33 | +21.4% |
| Aug 14, 2024 | After the close | -0.53 | -0.42 | +20.8% |
| May 14, 2024 | After the close | -0.73 | -0.32 | +56.2% |
| Feb 27, 2024 | Before the open | -0.80 | -0.72 |
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly…
| +10.0% |
| Nov 3, 2023 | Before the open | -0.91 | -0.73 | +19.8% |
| Aug 8, 2023 | After the close | -1.25 | -1.16 | +7.2% |
| May 9, 2023 | After the close | -1.26 | -1.31 | -4.0% |
| Feb 28, 2023 | After the close | -1.42 | -1.18 | +16.9% |
| Nov 8, 2022 | After the close | -1.75 | -1.89 | -8.0% |
| Aug 4, 2022 | After the close | -1.42 | -1.31 | +7.7% |
| May 5, 2022 | After the close | -1.52 | -1.27 | +16.4% |
| Feb 22, 2022 | After the close | -1.49 | -1.42 | +4.7% |
| Nov 4, 2021 | After the close | -1.19 | -1.14 | +4.2% |
| Aug 5, 2021 | After the close | -0.93 | -0.84 | +9.7% |
| May 4, 2021 | After the close | -0.97 | -0.76 | +21.6% |
| Feb 16, 2021 | After the close | -0.86 | -0.79 | +8.1% |
| Nov 5, 2020 | After the close | -0.90 | -1.01 | -12.2% |
| Aug 11, 2020 | After the close | -0.84 | -0.94 | -11.9% |
| May 12, 2020 | After the close | -0.85 | -1.15 | -35.3% |
| Mar 18, 2020 | After the close | -9.21 | -6.18 | +32.9% |
| Nov 27, 2019 | Time not confirmed | -7.60 | -7.60 | 0.0% |
| Sep 9, 2019 | Time not confirmed | — | -0.17 | — |